Boulevard Bio dreams big in immunology with $65M, sights on Vera's IgAN drug
Though it's no longer unusual for a startup to emerge with an investigational drug from China, an immunology biotech is adding that asset to two immune-resetting drugs it already discovered in-house. Boulevard ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.